Targeted treatment for glioblastoma using a new drug approach
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
This study is testing a new treatment for glioblastoma, a tough type of brain cancer, using a special method to deliver targeted medicine directly to the tumor while protecting healthy brain tissue, and it has shown encouraging results in dogs with similar tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-11001446 on NIH RePORTER |
What this research studies
This research focuses on developing a novel immunotherapy for glioblastoma (GBM), a challenging brain cancer. It utilizes a combination of targeted cytotoxins delivered through a specialized method called convection-enhanced delivery, which aims to directly attack tumor cells while minimizing damage to surrounding healthy tissue. The approach is based on the overexpression of specific receptors in GBM cells, allowing for precise targeting. Previous trials in dogs with similar tumors have shown promising results, including significant tumor reduction and improved survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to existing treatments.
Not a fit: Patients with other types of brain tumors or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with glioblastoma.
How similar studies have performed: This approach has shown success in preliminary trials with canine patients, indicating potential for effectiveness in human cases.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Debinski, Waldemar — Wake Forest University Health Sciences
- Study coordinator: Debinski, Waldemar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.